Kymera Therapeutics Q3 2023 Earnings Report $36.81 -0.61 (-1.63%) As of 02/21/2025 04:00 PM Eastern Earnings HistoryForecast Kymera Therapeutics EPS ResultsActual EPS-$0.90Consensus EPS -$0.73Beat/MissMissed by -$0.17One Year Ago EPSN/AKymera Therapeutics Revenue ResultsActual Revenue$4.73 millionExpected Revenue$14.53 millionBeat/MissMissed by -$9.80 millionYoY Revenue GrowthN/AKymera Therapeutics Announcement DetailsQuarterQ3 2023Date11/2/2023TimeN/AKYMR Upcoming EarningsKymera Therapeutics will be holding an earnings conference call on Thursday, February 27 at 8:30 AM Eastern. Interested parties can register for or listen to the call. Conference Call ResourcesPress ReleaseKYMR Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Kymera Therapeutics Earnings HeadlinesKymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27February 20 at 11:23 AM | markets.businessinsider.comKymera Therapeutics to Participate in Upcoming February Investor ConferencesJanuary 30, 2025 | globenewswire.comBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.February 23, 2025 | Brownstone Research (Ad)Kymera TherapeuticsJanuary 17, 2025 | forbes.comKymera Therapeutics: Strategic Advancements and Strong Financials Bolster Buy Rating by AnalystJanuary 17, 2025 | markets.businessinsider.comBank of America Securities Remains a Hold on Kymera Therapeutics (KYMR)January 16, 2025 | markets.businessinsider.comSee More Kymera Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kymera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kymera Therapeutics and other key companies, straight to your email. Email Address About Kymera TherapeuticsKymera Therapeutics (NASDAQ:KYMR), a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.View Kymera Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)ONEOK (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Home Depot (2/25/2025)Public Storage (2/25/2025)Sempra (2/25/2025)NVIDIA (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
